Tech Company Financing Transactions
Aprea Therapeutics Funding Round
On 12/3/2018, Aprea Therapeutics landed $56.9 million in Series C financing from Redmile Group, 5AM Ventures and Healthcap Venture Capital.
Transaction Overview
Company Name
Announced On
12/3/2018
Transaction Type
Venture Equity
Amount
$56,869,550
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance the clinical development of APR-246, a first-in-class anticancer agent that reactivates mutated p53 tumor suppressor protein.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
535 Boylston St.
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Aprea Therapeutics (Nasdaq: APRE) is a Stockholm, Sweden and Boston, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein, p53.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christian Schade
Chief Medical Officer
Eyal Attar
Chief Scientific Officer
Lars Abrahmsen
VP - Bus. Development
Gregory Korbel
Browse more venture capital transactions:
Prev: 12/3/2018: Salted venture capital transaction
Next: 12/3/2018: Wave Computing venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs